Walter Greenleaf, PhD

Walter Greenleaf, PhD

Walter Greenleaf is a research scientist, trained in Neuro and Behavioral Science. He is also a medical product developer. His focus has been on computer supported clinical products, with a specific focus on virtual reality and digital health technology. He’s proud of the products that he and his colleagues have developed and brought to market. He’s been active in developing Clinical Virtual Reality Systems for more than 30 years.

Walter recently served as the Director of the Mind Division, Stanford Center on Longevity. He is currently a Distinguished Visiting Scholar at Stanford University’s MediaX Program and a Visiting Scholar at Stanford’s Virtual Human Interaction Lab. He is Co-Founder of Virtual Ventures, the Chief Science Officer at Pear Therapeutics and Cognitive Leap, and Director of Technology Strategy for the National Behavioral Health Innovation Center.

His doctoral research at Stanford in Neuro & Behavioral Science focused on the interaction between hormones and human behavior. While working on his dissertation, Walter founded the first of several successful medical product companies. He has since maintained this dual-role in academics and business – lecturing, conducting research and publishing, while concurrently developing and bringing medical products to market.

As a pioneer that has remained active in the development of medical applications of Virtual Reality Technology, he also frequently contributes to the field as keynote speaker, as an editor for a leading journal, and as a conference organizer.

Specialties: Walter’s product designs include applications in; surgical simulation, 3D medical visualization, telerehabilitation, clinical informatics and decision support, ergonomic evaluation technology, automatic sleep-staging, psychophysiological assessment, as well as simulation-assisted rehabilitation technologies.

In behavioral medicine Walter has developed and helped bring to market systems for the treatment of PTSD, anxiety disorders, autism spectrum disorders and addictions.